Clinical trial

Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"

NCT01030861

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2010-08-01

PhasePHASE2

Study timeline

Study start (actual)2010-08-01Date precision: month

Registry last updated2020-08-05

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Autoantibody Positiveunresolved

Non-diabetic Relatives at Risk for Type 1 Diabetesunresolved

High Riskunresolved

Impaired Glucose Toleranceunresolved

Interventions

TeplizumabDRUG · verified · RxNorm: teplizumab

Placebo infusionDRUG

Sponsors & collaborators

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)lead sponsor

National Institute of Allergy and Infectious Diseases (NIAID)collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)collaborator

National Center for Research Resources (NCRR)collaborator

Juvenile Diabetes Research Foundationcollaborator

American Diabetes Associationcollaborator

Mapped research locations

San FranciscoCalifornia, United States2 New YorkNew York, United States1 HoustonTexas, United States1 DallasTexas, United States1 MiamiFlorida, United States1 TorontoOntario, Canada1 NashvilleTennessee, United States1 SeattleWashington, United States1 PittsburghPennsylvania, United States1 TampaFlorida, United States1 IndianapolisIndiana, United States1 MinneapolisMinnesota, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01030861 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.